[1] Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine‑Mediated Regulation of CD8 T‑Cell Responses During Acute and Chronic Viral Infection. Cold Spring Harb Perspect Biol. 2019 Jan 2;11(1):a028464.
[2] Sprent J, Boyman O. Optimising IL‑2 for Cancer Immunotherapy. Immune Netw. 2024 Jan 26;24(1):e5.
[3] Dong C. Cytokine Regulation and Function in T Cells. Annu Rev Immunol. 2021 Apr 26;39:51‑76.
[4] Bell M, Gottschalk S. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Front Immunol. 2021 Jun 4;12:684642.
[5] Pietrobon V, Todd LA, Goswami A, et al. Improving CAR T‑Cell Persistence. Int J Mol Sci. 2021 Oct 7;22(19):10828.
[6] Deng S, Sun Z, Qiao J, et al. Targeting tumors with IL‑21 reshapes the tumor microenvironment by proliferating PD‑1intTim‑3‑CD8+ T cells. JCI Insight. 2020 Apr 9;5(7):e132000.
[7] Tovar Manzano D, et al. Tumor‑infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer. Cell Oncol (Dordr). 2025 Dec;48(6):1659‑1675.
[8] Ghaffari S, et al. Optimising interleukin‑2 concentration, seeding density and bead‑to‑cell ratio of T‑cell expansion for adoptive immunotherapy. BMC Immunol. 2021 Jul 3;22(1):43.
[9] Boustani J, et al. Cisplatin‑based chemoradiation decreases telomerase‑specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunol. 2021 Jun 18;22(1):38.
[10] Pan C, Li J, Chen S, Yu H, Ye Y. [IL‑7/IL‑15/IL‑21/IL‑23 effectively promote the generation of human CD8+ central memory T cells in vitro]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021 Oct;37(10):872‑880.
[11] Dong J, Yang SX, Li Y, Gao JP, Zhang X. [In vitro expansion of T cells stimulated by combination of IL‑2, IL‑7 and IL‑15]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1590‑4.
[12] Abdelsamed HA, Zebley CC, Youngblood B. Epigenetic Maintenance of Acquired Gene Expression Programs during Memory CD8 T Cell Homeostasis. Front Immunol. 2018 Jan 18;9:6.